Ondine Biomedical Inc. Announces Leeds Teaching Hospital NHS Trust to use Steriwave

VANCOUVER, BC / ACCESSWIRE / August 6, 2024 / Ondine Biomedical Inc. (LON:OBI) and Iskus Health have announced that Leeds Teaching Hospitals NHS Trust will begin using Steriwave® nasal decolonization technology later this month. Leeds Teaching Hospitals NHS Trust handles 1.5 million patients annually, making it one of the country's largest acute trusts.

Steriwave will support a quality improvement initiative aimed at preventing infections in patients undergoing endonasal endoscopic anterior skull base surgery. The initiative's primary goals are to reduce post-operative antibiotic use within 30 days of surgery and decrease the need for follow-up appointments to treat infections.

Paul Nix, a rhinology and anterior skull base surgeon at Leeds Teaching Hospitals, will lead the initiative. He lauded the minimally invasive approach of operating through the nose but highlighted the infection risks associated with accessing the surgical site via the nasal passage, a known pathogen reservoir. Nix emphasized the benefits of Steriwave, which can be administered on short notice and works instantly.

Steriwave uses a light-activated agent to eliminate pathogens quickly and effectively. This method helps avoid the development of antimicrobial resistance, an essential aspect of the UK's 5-year plan for combating antimicrobial resistance published in May 2024.

In March 2024, Mid Yorkshire Teaching NHS Trust became the first in the UK to adopt Steriwave commercially for hip and knee surgery patients. By June 2024, Steriwave was added to the NHS Supply Chain, making it easier for NHS hospitals to purchase.